Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab

Inclusion Criteria

• •CD20 and CD22-positive, B-cell NHL which has progressed after 1 or 2 prior therapies.
• •Prior therapy must have contained at least one dose of Rituximab therapy. Patients can not be refractory to Rituximab (refractory = PD under treatment or within 6 month
• •Eastern Cooperative Oncology Group (ECOG) performance status: 0/ 1.
• •Patients must not have received previous radioimmunotherapy.
• •Patients tolerant to Rituximab.
• •Patients must not have received chemotherapy, cancer immunosuppressive therapy, growth factors (except erythropoietin), or investigational agents within 28 days before first dose of test article.